TY - JOUR
T1 - Update on Kaposi's sarcoma
T2 - A gammaherpesvirus-induced malignancy
AU - Kumar, Pallavi P.
AU - Little, Richard F.
AU - Yarchoan, Robert
N1 - Funding Information:
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1868, Building 10, Room 10S255, Bethesda, MD 20892-1868, USA. E-mail: ryln@nih.gov Current Infectious Disease Reports 2003, 5:85–92 Current Science Inc. ISSN 1523-3847 Copyright © 2003 by Current Science Inc.
PY - 2003/2
Y1 - 2003/2
N2 - Since the beginning of the AIDS epidemic, Kaposi's sarcoma (KS) has been one of the most visible manifestations of this disease and one of the most distressing for affected patients. The discovery in 1994 of a new gamma-herpesvirus, called Kaposi's sarcoma-associated herpes-virus, has led to increased understanding of the pathogenesis of this disease and the potential for new specific therapy. In addition, the development of highly active antiretroviral therapy has had a substantial impact on the incidence of KS in countries where it is available and on the course of established disease. Finally, recent advances in our understanding of angiogenesis have the potential of leading to new KS therapies. In this article we review some of the recent advances in the epidemiology and pathogenesis of KS, review the current treatment of this disease, and discuss several therapeutic approaches that are now under development.
AB - Since the beginning of the AIDS epidemic, Kaposi's sarcoma (KS) has been one of the most visible manifestations of this disease and one of the most distressing for affected patients. The discovery in 1994 of a new gamma-herpesvirus, called Kaposi's sarcoma-associated herpes-virus, has led to increased understanding of the pathogenesis of this disease and the potential for new specific therapy. In addition, the development of highly active antiretroviral therapy has had a substantial impact on the incidence of KS in countries where it is available and on the course of established disease. Finally, recent advances in our understanding of angiogenesis have the potential of leading to new KS therapies. In this article we review some of the recent advances in the epidemiology and pathogenesis of KS, review the current treatment of this disease, and discuss several therapeutic approaches that are now under development.
UR - http://www.scopus.com/inward/record.url?scp=3142558075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142558075&partnerID=8YFLogxK
U2 - 10.1007/s11908-003-0069-8
DO - 10.1007/s11908-003-0069-8
M3 - Review article
AN - SCOPUS:3142558075
SN - 1523-3847
VL - 5
SP - 85
EP - 92
JO - Current Infectious Disease Reports
JF - Current Infectious Disease Reports
IS - 1
ER -